Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers
about
Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistanceTherapeutic strategies with oral fluoropyrimidine anticancer agent, S-1 against oral cancer.Metastatic primary duodenal adeno-carcinoma responding to metronomic oral cyclophosphamide chemotherapyLessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, Milan.Metronomic ceramide analogs inhibit angiogenesis in pancreatic cancer through up-regulation of caveolin-1 and thrombospondin-1 and down-regulation of cyclin D1.The pharmacological bases of the antiangiogenic activity of paclitaxel.VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide.Metronomic chemotherapy: possible clinical application in advanced hepatocellular carcinomaCelecoxib and octreotide synergistically ameliorate portal hypertension via inhibition of angiogenesis in cirrhotic rats.Next generation metronomic chemotherapy-report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6-8 May 2016, Mumbai.Effect of celecoxib plus standard chemotherapy on serum levels of vascular endothelial growth factor and cyclooxygenase-2 in patients with gastric cancer.Metronomic chemotherapy for cancer treatment: a decade of clinical studies.Metronomics: towards personalized chemotherapy?A systematic literature analysis of correlative studies in low-dose metronomic chemotherapy trials.Soluble vascular endothelial-cadherin and auto-antibodies to human vascular endothelial-cadherin in human diseases: Two new biomarkers of endothelial dysfunction.Recent advances for the treatment of pancreatic and biliary tract cancer after first-line treatment failure.Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: current status and future development.Current achievements and future perspectives of metronomic chemotherapy.Resistance to metronomic chemotherapy and ways to overcome it.Successful Outcome of Low-Dose S-1 Used to Treat Buccal Squamous Cell Carcinoma.Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells.Local Radiotherapy Affects Drug Pharmacokinetics-Exploration of a Neglected but Significant Uncertainty of Cancer Therapy.Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients.Metastatic breast cancer patients treated with low-dose metronomic chemotherapy with cyclophosphamide and celecoxib: clinical outcomes and biomarkers of response.Continuous, low-dose capecitabine for patients with recurrent colorectal cancer.Optimization of biomarkers-based classification scores as progression-free survival predictors: an intuitive graphical representation
P2860
Q27023579-23107D1A-DA97-4DF4-9B96-52514EF85254Q33884698-D2E2332F-B84D-46BC-81FC-A93E2813842AQ34131391-0AD9C6F1-4C65-4A45-9167-F64FDED475D5Q34173001-BD9E4FB4-5787-45BF-BB1D-2353FB314809Q36282739-D8FFEB15-CE3D-4820-857B-43A9F9DDC16BQ36927558-33494647-4D24-48D9-A383-79EDA060E89BQ37111160-B83078DD-D7F8-4C21-9E67-180FCB333389Q37236004-842A10AE-98F2-48E2-828C-BEDBD83BCC64Q37262768-7F2A7F0D-8F0C-4F5A-A3A2-7B9746BAC190Q37458763-5BDFFD36-ABB2-4E24-9541-72DF326B1AF9Q37567760-6ECDAB11-40E7-4256-899F-F2EB92857F9FQ38087885-A1ED4096-FBBB-4056-8B15-CB198E288300Q38218923-B79CF467-1A5B-486C-8EF6-31BEA7F00BAAQ38249998-94B3909C-D184-482A-AB68-35C080030FF1Q38541002-B8E4AA8C-C920-4283-8D76-5FF56E674DBFQ38577917-0254A486-46D0-4963-A816-02E52A7D2C66Q38638654-A2263370-75A2-40E7-9CD9-6796EC681C36Q38788234-9EE5AF9B-0E0E-4E2C-9C05-179811558076Q40448516-DA76EC09-6EAC-410B-81C2-82A902544F2CQ41215144-D9B64D28-2058-4EA2-993F-6DF072DBEA0BQ44084942-D617DC08-A2DF-4841-80FF-048C52097D5CQ50052519-43954F3A-1C66-4B5E-9707-D33FE6EFB548Q52852575-94C3CCBD-6204-4A3D-BF7C-0C891B1AC4F3Q53223630-C4EC7068-0A94-481A-8AC9-8EC6320C0BCBQ53630314-4C68BA1C-9E5F-43FF-B705-C42B93F5CDFCQ59131898-09207343-4C53-4C7D-B1B5-DAA9AC97A1CF
P2860
Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Clinical, pharmacokinetic and ...... ctory gastrointestinal cancers
@ast
Clinical, pharmacokinetic and ...... ctory gastrointestinal cancers
@en
type
label
Clinical, pharmacokinetic and ...... ctory gastrointestinal cancers
@ast
Clinical, pharmacokinetic and ...... ctory gastrointestinal cancers
@en
prefLabel
Clinical, pharmacokinetic and ...... ctory gastrointestinal cancers
@ast
Clinical, pharmacokinetic and ...... ctory gastrointestinal cancers
@en
P2093
P2860
P50
P1433
P1476
Clinical, pharmacokinetic and ...... ctory gastrointestinal cancers
@en
P2093
Andrea Ciarlo
Andrea Fontana
Anna Fioravanti
Bastianina Canu
Giacomo Allegrini
Giada Arrighi
Gianluca Masi
Giovanni Brandi
Guido Bocci
Maria Teresa Barletta
P2860
P2888
P304
P356
10.1007/S10456-012-9260-6
P577
2012-03-02T00:00:00Z